MAP Pharmaceuticals leads with $25.2 million round.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
MAP Pharmaceuticals
|
$25.25 million
|
Brookside Capital |
The money will be used primarily to advance the Phase II clinical development of the company's two lead drug candidates for the treatment of asthma and migraine. |
|
CoLucid Pharmaceuticals
|
$16 million
|
Domain Associates, Pappas Ventures |
The company was formed with a novel clinical stage migraine molecule licensed from Eli Lilly. |
|
Chlorogen
|
$6 million
|
Burrill & Co. |
Chlorogen produces therapeutic proteins in tobacco. |
|
Neuroptix
|
$500,000
|
Launchpad Venture Group |
Neuroptix is focused on the diagnosis and management of Alzheimer's and other degenerative neurological and ophthalmologic disorders. |